Real-world systemic treatment outcomes for moderate-to-severe atopic dermatitis in children by skin color: 4-year results from the observational, international, real-world PEDISTAD registry.
文献摘要
Background Atopic dermatitis (AD) can have different genetic, immunopathogenic, and clinical features depending on the ethnicity of the affected individual. Objective To investigate if White and non-White children with moderate-to-severe AD respond differently to systemic treatment. Methods PEDISTAD is an observational, international, real-world study. Patients were analyzed in 2 subgroups: non-White and White. Non-White included Black/African American, Asian, American Indian or Alaskan-Native and Multiracial. Results 314 White, and 186 non-White children Conclusion In this study, patients that received dupilumab had a greater observed improvement in clinician- and patient-reported outcomes compared with patients receiving methotrexate and cyclosporine irrespective of skin color/race.